Logo image of LPCN

LIPOCINE INC (LPCN) Stock Fundamental Analysis

NASDAQ:LPCN - Nasdaq - US53630X2036 - Common Stock - Currency: USD

3.38  -0.21 (-5.85%)

After market: 3.5 +0.12 (+3.55%)

Fundamental Rating

3

Taking everything into account, LPCN scores 3 out of 10 in our fundamental rating. LPCN was compared to 194 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for LPCN as it has an excellent financial health rating, but there are worries on the profitability. LPCN is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year LPCN has reported negative net income.
In the past year LPCN has reported a negative cash flow from operations.
LPCN had negative earnings in each of the past 5 years.
LPCN had a negative operating cash flow in each of the past 5 years.
LPCN Yearly Net Income VS EBIT VS OCF VS FCFLPCN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -5M -10M -15M -20M

1.2 Ratios

LPCN has a better Return On Assets (-19.60%) than 62.70% of its industry peers.
Looking at the Return On Equity, with a value of -21.22%, LPCN is in the better half of the industry, outperforming 70.27% of the companies in the same industry.
Industry RankSector Rank
ROA -19.6%
ROE -21.22%
ROIC N/A
ROA(3y)-33.65%
ROA(5y)-49.96%
ROE(3y)-37.29%
ROE(5y)-91.07%
ROIC(3y)N/A
ROIC(5y)N/A
LPCN Yearly ROA, ROE, ROICLPCN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -50 -100 -150 -200

1.3 Margins

LPCN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LPCN Yearly Profit, Operating, Gross MarginsLPCN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -2K -4K -6K -8K

More info and screens

7

2. Health

2.1 Basic Checks

LPCN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for LPCN has been increased compared to 1 year ago.
LPCN has more shares outstanding than it did 5 years ago.
There is no outstanding debt for LPCN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
LPCN Yearly Shares OutstandingLPCN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 1M 2M 3M 4M 5M
LPCN Yearly Total Debt VS Total AssetsLPCN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M

2.2 Solvency

LPCN has an Altman-Z score of -6.14. This is a bad value and indicates that LPCN is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -6.14, LPCN is doing worse than 67.03% of the companies in the same industry.
There is no outstanding debt for LPCN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -6.14
ROIC/WACCN/A
WACC9.77%
LPCN Yearly LT Debt VS Equity VS FCFLPCN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M 40M

2.3 Liquidity

A Current Ratio of 12.97 indicates that LPCN has no problem at all paying its short term obligations.
With an excellent Current ratio value of 12.97, LPCN belongs to the best of the industry, outperforming 85.95% of the companies in the same industry.
A Quick Ratio of 12.97 indicates that LPCN has no problem at all paying its short term obligations.
LPCN has a Quick ratio of 12.97. This is amongst the best in the industry. LPCN outperforms 87.03% of its industry peers.
Industry RankSector Rank
Current Ratio 12.97
Quick Ratio 12.97
LPCN Yearly Current Assets VS Current LiabilitesLPCN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M

More info and screens

4

3. Growth

3.1 Past

LPCN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 76.43%, which is quite impressive.
The Revenue has grown by 358.08% in the past year. This is a very strong growth!
EPS 1Y (TTM)76.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%67.72%
Revenue 1Y (TTM)358.08%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%100%

3.2 Future

The Earnings Per Share is expected to grow by 17.34% on average over the next years. This is quite good.
The Revenue is expected to grow by 79.61% on average over the next years. This is a very strong growth
EPS Next Y75.59%
EPS Next 2Y22.41%
EPS Next 3Y17.34%
EPS Next 5YN/A
Revenue Next Year436.5%
Revenue Next 2Y61.85%
Revenue Next 3Y41.79%
Revenue Next 5Y79.61%

3.3 Evolution

LPCN Yearly Revenue VS EstimatesLPCN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 20M 40M 60M 80M
LPCN Yearly EPS VS EstimatesLPCN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -5 -10 -15 -20 -25

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

LPCN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year LPCN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LPCN Price Earnings VS Forward Price EarningsLPCN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LPCN Per share dataLPCN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

A more expensive valuation may be justified as LPCN's earnings are expected to grow with 17.34% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.41%
EPS Next 3Y17.34%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for LPCN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LIPOCINE INC

NASDAQ:LPCN (2/21/2025, 8:00:00 PM)

After market: 3.5 +0.12 (+3.55%)

3.38

-0.21 (-5.85%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-07 2024-11-07/bmo
Earnings (Next)03-05 2025-03-05/amc
Inst Owners9.16%
Inst Owner Change-96.23%
Ins Owners2.91%
Ins Owner Change0%
Market Cap18.08M
Analysts82.86
Price Target10.2 (201.78%)
Short Float %1.5%
Short Ratio2.31
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)22.74%
Min EPS beat(2)17.12%
Max EPS beat(2)28.36%
EPS beat(4)4
Avg EPS beat(4)63.26%
Min EPS beat(4)12.39%
Max EPS beat(4)195.16%
EPS beat(8)5
Avg EPS beat(8)10.78%
EPS beat(12)8
Avg EPS beat(12)133.25%
EPS beat(16)12
Avg EPS beat(16)106.23%
Revenue beat(2)0
Avg Revenue beat(2)-84.86%
Min Revenue beat(2)-100%
Max Revenue beat(2)-69.72%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-8.11%
EPS NQ rev (3m)-8.11%
EPS NY rev (1m)3.31%
EPS NY rev (3m)6.41%
Revenue NQ rev (1m)92.63%
Revenue NQ rev (3m)92.63%
Revenue NY rev (1m)13.9%
Revenue NY rev (3m)11.43%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.28
P/FCF N/A
P/OCF N/A
P/B 0.95
P/tB 0.95
EV/EBITDA N/A
EPS(TTM)-0.74
EYN/A
EPS(NY)-1.53
Fwd EYN/A
FCF(TTM)-0.94
FCFYN/A
OCF(TTM)-0.93
OCFYN/A
SpS1.48
BVpS3.57
TBVpS3.57
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -19.6%
ROE -21.22%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-33.65%
ROA(5y)-49.96%
ROE(3y)-37.29%
ROE(5y)-91.07%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.38
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 272.63%
Cap/Sales 1.18%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 12.97
Quick Ratio 12.97
Altman-Z -6.14
F-Score4
WACC9.77%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)8.84%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)76.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%67.72%
EPS Next Y75.59%
EPS Next 2Y22.41%
EPS Next 3Y17.34%
EPS Next 5YN/A
Revenue 1Y (TTM)358.08%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%100%
Revenue Next Year436.5%
Revenue Next 2Y61.85%
Revenue Next 3Y41.79%
Revenue Next 5Y79.61%
EBIT growth 1Y70.43%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-327.32%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-337.98%
OCF growth 3YN/A
OCF growth 5YN/A